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ABSTRACT
Background We estimated the cost- effectiveness of 
universal DNA screening for Lynch syndrome (LS) among 
newly diagnosed patients with colorectal cancer (CRC) 
followed by cascade screening of relatives from the Swiss 
healthcare system perspective.
Methods We integrated decision trees with Markov 
models to calculate incremental cost per quality- adjusted 
life- year saved by screening all patients with CRC 
(alternative strategy) compared with CRC tumour- based 
testing followed by DNA sequencing (current strategy).
Results The alternative strategy has an incremental 
cost- effectiveness ratio of CHF65 058 compared with 
the current strategy, which is cost- effective according to 
Swiss standards. Based on annual incidence of CRC in 
Switzerland, universal DNA screening correctly identifies 
all 123 patients with CRC with LS, prevents 17 LS deaths 
and avoids 19 CRC cases, while the current strategy 
leads to 32 false negative results and 253 LS cases 
lost to follow- up. One way and probabilistic sensitivity 
analyses showed that universal DNA testing is cost- 
effective in around 80% of scenarios, and that the cost 
of DNA testing and the number of invited relatives per LS 
case determine the cost- effectiveness ratio.
Conclusion Results can inform policymakers, healthcare 
providers and insurance companies about the costs and 
benefits associated with universal screening for LS and 
cascade genetic testing of relatives.
INTRODUCTION
Lynch syndrome (LS) is a cancer predisposition 
syndrome that confers a 12%–52% lifetime risk 
for colorectal cancer (CRC), and a 13%–60% life-
time risk for endometrial cancer, while the corre-
sponding risks in the general population are 
5%–6% and 2%–3%, respectively.1 LS is also asso-
ciated with glioblastomas and with gastric, ovarian, 
small bowel, pancreatic and urothelial cancers.2 
Germline pathogenic variants in mismatch repair 
(MMR) genes (ie, MLH1, MSH2, MSH6 or PMS2) 
or deletions in the 3’end of the EPCAM gene predis-
pose to LS.3 Pathogenic variants are inherited in an 
autosomal- dominant manner; for every LS case, 
there are multiple blood relatives with the same 
pathogenic variant. First- degree and second- degree 
relatives (FDR, SDR) have 50% and 25% proba-
bility, respectively, of inheriting the pathogenic 
variant.4
LS is a common cancer predisposition condition 
with an estimated population frequency 1:279.5 
However, LS remains largely undetected due to 
different associated cancer types and the lack of clear 
diagnostic criteria. The Amsterdam II and revised 
Bethesda guidelines that have been traditionally 
used to identify individuals at risk for LS can miss 
23%–50% of cases.6–8 Moreover, LS often occurs 
before screening recommendations apply, resulting 
in late identification of cases.9 Due to these limita-
tions, only a fraction of LS cases is referred for 
genetic evaluation and less than 10% receive genetic 
testing.10 Underdiagnosis of LS results in a significant 
number of patients and blood relatives not receiving 
appropriate care and in unnecessary and prevent-
able morbidity and mortality.11 LS cases with CRC 
can benefit from treatment with monoclonal anti-
bodies or immune check- point inhibitors in combi-
nation with adjuvant chemotherapy.12 Colonoscopy 
decreases CRC morbidity and mortality by detecting 
the disease at earlier stages and can also be preven-
tive by allowing for endoscopic removal of preneo-
plastic lesions/polyps.13 14 Additional prevention 
and screening methods, such as daily aspirin, upper 
gastrointestinal endoscopy and prophylactic surgery 
can be tailored to individual needs of LS cases.15
This study presents a Swiss- based cost- 
effectiveness analysis of genetic screening for LS 
provided to all newly diagnosed patients with 
CRC, followed by cascade genetic screening of 
blood relatives. Although LS cases may present 
with different forms of cancer, we focus on CRC 
because it is the most common cancer associated 
with the syndrome. Screening for LS among all 
newly diagnosed CRC cases, irrespective of age and 
family history, followed by cascade testing of blood 
relatives, has been embraced by the Evaluation of 
Genomic Applications in Practice and Prevention 
(EGAPP) Working Group.16 Blood relatives of LS 
cases can be tested inexpensively and with 100% 
accuracy, and those who test negative are excluded 
from early screening and preventive interventions.17 
Diagnosis of LS with this protocol has 85% sensi-
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We compared two strategies: the current strategy imple-
mented in Switzerland involves preliminary tumour testing with 
immunohistochemistry (IHC), BRAF V600E and germline DNA 
sequencing of a fraction of patients with CRC and inviting four 
FDR and/or SDR per every identified LS case for cascade testing. 
The alternative strategy involves DNA sequencing of all newly 
diagnosed patients with CRC, and inviting four FDR and/or SDR 
per every identified LS case for cascade testing. The alternative 
strategy does not include preliminary tumour testing but focuses 
on germline genetic testing of patients with CRC followed by 
cascade testing of relatives. The study examines whether the 
alternative strategy for identifying LS cases is economically 
reasonable, considering the perspective of the Swiss healthcare 
system.
MATERIALS AND METHODS
We developed an analytic model combining decision trees with 
Markov modelling to estimate the cost- effectiveness of universal 
screening for LS for all newly diagnosed patients with CRC 
followed by cascade testing. We estimated costs of tumour 
testing, DNA sequencing, colonoscopy and treatment. Decision 
trees represent the structure of LS screening, modelling possible 
decisions and outcomes and displaying the algorithm behind the 
processes leading to genetic testing. The integration of Markov 
modelling helped conduct probabilistic forecasting and predic-
tive modelling of future events to calculate costs and outcomes 
(number of CRC cases, deaths, CRC avoided) associated with 
genetic testing over the period of 50 years. Each Markov model 
is associated with a corresponding end node of the decision tree. 
To find incremental cost- effectiveness ratio (ICER), we calcu-
lated differences in total costs and number of gained quality- 
adjusted life years (QALYs) for each strategy (table 1).
Model inputs
Data on costs have been obtained from the University Hospital 
Basel, the Geneva University Hospitals and published litera-
ture.10 Costs applied in modelling include detection of LS cases 
among patients with CRC and relatives; colonoscopy; CRC 
treatment. Costs associated with detection of LS cases among 
CRC incident cases include genetic consultations; tumour- based 
testing (IHC for the four MMR proteins and BRAF V600E) 
and germline screening. In Switzerland, germline screening for 
LS diagnosis is conducted in two steps: sequencing of two to 
four MMR genes by next generation sequencing (NGS); Sanger 
sequencing of selected exons and gene dosage analysis by multi-
plex ligation- dependent probe amplification conducted to 
confirm NGS findings. Costs of LS screening for relatives include 
genetic consultations and carrier testing for the identified patho-
genic variant (cascade testing). All costs applied in modelling are 
provided in the supplementary materials and are expressed in 
2020 Swiss Francs (CHF).
Parameters used in decision trees and Markov modelling are 
based on an EGAPP review.16 All financial, epidemiological, and 
clinical model inputs, including sensitivity and specificity of 
IHC, BRAF V600E and DNA sequencing are literature- based10 
(see online supplemental materials). For IHC and BRAF V600E, 
we applied sensitivity of 83.0% and 69.0%, respectively, and 
specificity of 88.8% and 99.0% respectively. We assumed 99.5% 
sensitivity and 99.9% specificity of DNA sequencing. We also 
assumed that 79% of relatives testing positive for LS would 
accept increased surveillance. Transition probabilities between 
states (Healthy, CRC, mCRC, Death) and stage distributions 
of CRC in screened and unscreened populations are literature- 
based and were used to calculate costs of treatment of the corre-
sponding CRC stage.10 18 Risks associated with colonoscopy, such 
as perforation, bleeding and death, have also been incorporated 
into the model.19 20 To separate CRC- related deaths and deaths 
from other causes, we used annual crude death rate in Switzer-
land equal to 0 0079 in both strategies.21 Based on current Swiss 
practices, we assume that identified LS cases will invite four 
CRC- free FDR and/or SDR for cascade testing. Among relatives 
who agree to genetic testing, those who test positive for LS are 
offered biennial colonoscopy, starting at 25 years old.22 The 
probability of identifying the familial pathogenic variant among 
FDR is 45% and decreases to around 25% in SDR. The proba-
bility to identify LS cases with cascade testing in both FDR and 
SDR is around 35%.10 Both strategies were ranked according 
to costs in CHF and effects in QALYs. We calculated ICER of 
net costs per QALYs saved. The cost- effectiveness analysis was 
conducted based on the Consolidated Health Economic Evalua-
tion Reporting Standards statement.23
Decision trees
Decision trees represent the detailed structure of events and 
outcomes associated with each of the two strategies based on 
epidemiological data and Swiss clinical parameters for CRC and 
LS (see online supplemental materials). For the current strategy, 
we calculated the number of false negative and false positive 
results associated with IHC and BRAF V600 testing and we 
assessed the number of patients with CRC lost- to- follow up. For 
the alternative strategy, the decision tree allowed us to calculate 
the number of patients with CRC and relatives with pathogenic 
variants in MMR genes and to evaluate the number of individuals 
who develop CRC (figure 1).
The current strategy consists of three phases: identifying 
carriers of pathogenic variants in MMR genes among newly 
diagnosed patients with CRC by screening tumour tissue with 
IHC, BRAF V600E and DNA sequencing; offering carrier 
testing to FDR and/or SDR of identified LS cases; using colo-
noscopy for early detection of CRC among relatives with LS. 
IHC is conducted routinely in Switzerland and patients with loss 
of MLH1 expression undergo testing for BRAF V600E, while 
patients whose tumours demonstrate loss of MSH2, MSH6 or 
PMS2 expression undergo germline DNA sequencing directly 
after IHC. Cases identified with LS receive recommendations to 
notify their blood relatives for cascade testing. The cost of carrier 
Table 1 Key design criteria of the analysis
Population Individuals newly diagnosed with CRC and FDR and SDR
Intervention DNA sequencing of all newly diagnosed CRC cases and cascade 
genetic testing of  four or more FDR and SDR of identified LS 
cases
Comparator Current strategy with IHC, BRAF V600E and DNA sequencing 
for a proportion of newly diagnosed CRC cases and cascade 
testing of four FDR and/or SDR
Outcome QALYs saved
Model type Decision trees integrated with Markov models
Time horizon Lifetime/50 years
Perspective Swiss healthcare system
Costs Swiss francs (CHF)




CRC, colorectal cancer; FDR, first- degree relative; IHC, immunohistochemistry; LS, 
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testing for relatives is substantially lower because the location 
of the pathogenic variant is known (ie, CHF3500 for patients 
with CRC vs CHF400 for relatives). This cost is covered only 
for FDR in the Swiss healthcare system. The alternative strategy 
assumes universal germline testing for all newly- diagnosed CRC 
cases followed by cascade testing of four FDR and/or SDR of LS 
cases. The alternative strategy has high sensitivity and specificity 
to detect LS and is consistent with evidence- based recommen-
dations for cascade screening for ‘actionable’ hereditary cancer 
syndromes.4 18
Markov modelling
Markov modelling estimated the long- term costs and the number 
of annually gained QALYs in both strategies. Markov models 
were based on four states: healthy, CRC, metachronous CRC 
(mCRC) and death. Once a person is diagnosed with CRC, the 
disease could progress to mCRC or death. Markov models used 
1 year cycle length and were continued for 50 years, assuming 
that all cohort participants will be dead by the end of this time 
frame. We modelled annual transition probability from CRC to 
mCRC of around 1%, based on the risk of mCRC depending on 
the affected MMR gene and considering a time frame ranging 
from 6 months to 12 years post initial CRC diagnosis.24–26 We 
modelled risk of developing cancer (mCRC) among screened 
and unscreened populations according to evidence of frequency 
of colonoscopy and its CRC/mCRC risk reduction.13 26 Model-
ling assumptions are conservative, therefore, intentionally 
made unfavourable for the cost- effectiveness of the alternative 
strategy. Analyses were performed using Microsoft Excel 2016 
(Microsoft) with a discount rate of 3% for both costs and effects 
(see online supplemental materials).
Sensitivity analysis
A deterministic one- way sensitivity analysis estimated the effects 
of variations in each input parameter on overall cost- effectiveness 
of the alternative strategy. Probabilistic sensitivity analysis tested 
the robustness of our modelling and assessed the overall likeli-
hood of the alternative strategy to be not cost- effective. Probabi-
listic sensitivity analysis tested 1000 scenarios varying different 
parameters, such as number of CRC cases accepting germline 
genetic testing, number of relatives accepting carrier testing, 
probability to develop cancer among relatives positive for LS, 
compliance with colonoscopy and lost- to- follow up rate.
RESULTS
Decision trees
Modelling of the two LS screening strategies begins with a 
cohort of 4100 newly diagnosed patients with CRC, based on 
the annual number of CRC incident cases in Switzerland.27 
Assuming that 3% of all newly diagnosed patients with CRC 
are affected by LS, there are 123 LS cases with CRC.28 With the 
current strategy, all 4100 newly diagnosed patients with CRC 
are offered tumour- based testing. Among them, 32 cases have 
false negative results, while 33 patients with CRC are correctly 
identified with LS, counselled and invite relatives for cascade 
testing. With the current strategy, 253 patients with CRC are 
lost to follow- up before DNA sequencing. Using a conservative 
approach, we assumed that only 50% of relatives accept cascade 
testing, while only 79% of relatives identified with LS undergo 
biennial colonoscopy. With the alternative strategy, all 123 of 
4100 newly diagnosed patients with CRC are identified as LS 
cases, and 492 relatives are invited for cascade testing (see online 
supplemental materials). CRC stages are classified according to 
the Duke’s Classification.29
Markov modelling
Figure 2 shows the Markov models with transitions between 
the four disease states. The Markov models account for costs 
associated with colonoscopy and CRC treatment over 50 years. 
Each cancer- free relative diagnosed with LS is recommended 
to undergo biennial colonoscopy, starting at the age of 25. We 
assumed that colonoscopy decreases the lifetime risk of CRC 
by 67%; therefore, more LS cases tend to stay healthy during 
each following year compared with those who do not undergo 
colonoscopy. While colonoscopy is associated with higher costs 
of surveillance, it reduces overall treatment costs, due to early 
detection of CRC and mCRC while also having a favourable 
effect on stage distribution of CRC. Swiss anecdotal data suggest 
that a proportion of relatives who refuse cascade testing may 
still elect to have a colonoscopy every 3 years. We assumed that 
this frequency of colonoscopy also decreases the risk of CRC but 
only by 25%. Relatives testing negative for LS are assumed to 
have a population- level risk of CRC; therefore, they are offered 
colonoscopy screening every 10 years, starting at the age of 50 
(see online supplemental materials).
Total screening costs for patients with CRC and relatives 
ranged between CHF136 966 947 with the current strategy 
and CHF150 691 700 with the alternative strategy. ICER of 
Figure 1 Schematic representation of compared testing strategies 
for LS for patients newly diagnosed with CRC. (A) Strategy 1 represents 
current screening for LS including two tumour analyses (IHC and BRAF 
V600), followed by DNA sequencing for suspicious cases. (B) Strategy 2 
represents alternative universal DNA sequencing for all CRC cases followed 
by cascade genetic testing of relatives of mutation carriers. CRC, colorectal 
cancer; IHC, immunohistochemistry; LS, Lynch syndrome.
Figure 2 Markov model with the modelled transition probabilities 
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universal LS screening with cascade testing of four relatives is 
CHF65 058 per QALY gained. This is cost- effective in Swiss 
healthcare settings, where the cost- effectiveness threshold is 
assumed to be CHF100 000 per QALY saved. The expected 
discounted gained QALYs ranged between CHF361 147 with 
the current strategy and CHF361 358 in the alternative strategy. 
Universal LS screening gained 211 more QALYs at the additional 
cost of CHF13 724 753 compared with the current strategy 
(table 2). LS is associated with high rates of secondary CRC; 
therefore, mCRC was incorporated into our model to calculate 
associated costs and mortality. According to our model, the alter-
native strategy prevents 17 deaths at the cost of CHF785 645 
per death avoided. Moreover, the alternative strategy avoids 18 
cases of CRC and one case of mCRC, compared with the current 
strategy (table 3).
Sensitivity analyses
Figure 3 shows results of one- way sensitivity analysis using 11 
parameters in descending importance. This analysis revealed 
that the number of invited relatives and cost of germline DNA 
sequencing for patients with CRC had a major impact on 
the outcome. Decreasing the cost of DNA sequencing from 
CHF3500 to CHF2500 reduces the ICER of the alternative 
strategy to CHF49 947. Costs of tumour tests and carrier testing 
for relatives did not have a substantial effect on the overall cost- 
effectiveness of the alternative strategy. In cases when only two 
relatives per LS case are invited for cascade testing, the alter-
native strategy costs CHF123 483 per QALY and is not cost- 
effective. Reducing the risk of CRC in relatives diagnosed with 
LS to 25% increases the cost of the programme to CHF103 385 
per QALY, exceeding the cost- effectiveness threshold.
Probabilistic sensitivity analysis was conducted using five 
parameters, that is, patients with CRC lost- to- follow up, number 
of invited relatives per LS case, proportion of tested relatives 
and compliance with biennial colonoscopy. Results of prob-
abilistic sensitivity analysis suggest that the number of invited 
relatives per LS case is the most influential factor affecting the 
overall cost- effectiveness of the alternative strategy. In a Monte- 
Carlo simulation of 5000 scenarios, the ICER of the alterna-
tive strategy varied between CHF33 075 and CHF316 010, 
with a mean of CHF73 792. Increasing the number of invited 
relatives from four to seven decreases the ICER from CHF65 
058 to about CHF45 000. Given 50% acceptance rate among 
relatives, increasing the number of invited relatives by one per 
LS case decreases the ICER on average by CHF5000. Including 
SDR reduces the ICER from CHF65 058 to CHF32 886. Finally, 
increasing the frequency of colonoscopy from biennial to annual 
increases the ICER from CHF65 058 to CHF70 536 per QALY 
gained. The universal strategy has a probability of 80% to be 
cost- effective given the threshold of CHF100 000 per QALY. 
We assumed normal distribution in epidemiological and clinical 
parameters and gamma distribution in costs.
DISCUSSION
We estimated the cost- effectiveness of universal screening for 
LS among all newly diagnosed patients with CRC with cascade 
testing of relatives as a measure of identifying LS cases. Our 
cost- effectiveness analysis incorporated costs of carrier testing of 
relatives, an aspect that is often omitted from cost- effectiveness 
analyses of genetic testing technologies.30 Universal LS screening 
with cascade testing of relatives is cost- effective in around 80% 
of scenarios. The alternative strategy prevents 17 deaths at the 
cost of CHF785 645 per death avoided, with ICER of CHF65 
058 per QALY saved and below the acceptable Swiss cost- 
effectiveness threshold of CHF100 000. Since the risk of death 
from other causes was equal in both strategies, the observed 
difference of 17 deaths is associated with CRC. The number 
of prevented deaths is associated with annual transitions from 
Healthy to CRC, and from CRC to death, which are substan-
tially lower in tested and screened populations.13
The current strategy for LS screening in Switzerland involves 
two tumour- based tests (IHC and BRAF V600) followed by DNA 
sequencing. It is possible that anticipating results from three 
sequential tests, including tumour biopsy, causes discomfort to 
patients and their families, resulting in 64% lost- to- follow- up 
rate among patients with CRC.31 Germline DNA screening has 
almost 100% validity and, therefore, identifies all LS cases and 
eliminates false negative and false positive diagnoses. This may 
result in modification of CRC treatment with better patient 
outcomes.12 It also prevents patients with CRC from being lost- 
to- follow- up and deaths of undiagnosed LS cases and identifies 
a higher number of cancer- free relatives and new CRC cases 
at early stages through colonoscopy screening. The advantages 
of universal LS screening are to simplify the process of identi-
fying LS cases, possibly provide personalised treatment to those 
with CRC and to identify cancer- free relatives with LS who can 
benefit from colonoscopy screening starting at a younger age. 
Despite wide application of the Bethesda and Amsterdam guide-
lines for initiating LS screening, they are not routinely applied in 
Switzerland because they can miss up to 50% of LS cases due to 
poor data quality, small family size or lack of awareness of cancer 
cases in the family.6 Implementing these criteria is also associated 
with more costs and burden of data collection, interpretation 
and quality assurance.
Table 2 Costs associated with genetic testing for LS
Costs for cohort (CHF) Current strategy Alternative strategy
IHC 1 476 000 0
BRAF V600E 50 809 0
DNA sequencing 497 808 14 350 000
DNA sequencing for relatives 29 442 110 700
Colonoscopy and treatment 134 912 887 136 231 000
Total 136 966 947 150 691 700
QALYs gained 361 147 361 358
Cost difference 13 724 753
QALYs difference 211
ICER 65 058
ICER, incremental cost- effectiveness ratio; IHC, immunohistochemistry; LS, Lynch 
syndrome; QALYs, quality- adjusted life years.
Table 3 Health outcomes associated with compared screening 
strategies
Health outcome (N) Current strategy Alternative strategy Difference
QALYs gained 361 147 361 358 211
Relatives with CRC 814 795 −18
Relatives with mCRC 33 32 −1
Deaths 5612 5595 −17
Patients with CRC with 
LS identified
33 123 90
Relatives with LS 
identified
29 111 81
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Despite the significant cost associated with offering DNA 
testing to all patients with CRC, universal LS screening improves 
the overall utility of genetic testing at a reasonable cost. Proba-
bilistic sensitivity analysis revealed that universal LS screening is 
cost- effective in around 80% of scenarios, while one- way sensi-
tivity analysis showed that it is cost- effective in the majority of 
possible scenarios. Our model was limited to LS and germline 
sequencing to either two or four MMR genes, while NGS- panel 
testing is highly advisable for all CRC cases because it can iden-
tify several other cancer syndromes.32 Identification of non- LS- 
associated CRC cases would likely increase the cost- effectiveness 
of universal LS screening as more families with inherited predis-
position to cancer would be identified and provided with risk 
reducing strategies.
One scenario that was unfavourable for universal LS screening 
was to decrease the number of invited relatives to two per LS 
case. This scenario increases the ICER to about CHF123 000, 
which is unfavourable for the Swiss healthcare system. Although 
our models assumed testing of four relatives per LS case, Swiss 
data demonstrate that four LS cases invited more than 50 rela-
tives for cascade testing.31 Implementing strategies to facilitate 
cascade testing, for example, mailing of saliva kits and family- 
based telephone or web- based counselling, holds promise to 
enhance the cost- effectiveness of universal LS screening.33 34 
Expanding insurance coverage to SDR, who are currently not 
covered for carrier testing in the Swiss healthcare system, will 
increase identification of an underdiagnosed syndrome at the 
population level and significantly reduce the time needed to 
detect LS predisposing variants.35 Moreover, although the cost 
of targeted testing is significantly lower (CHF400 vs CHF3500), 
lack of insurance coverage for cascade testing may be a significant 
barrier accessing specialised genetic services for segments of the 
population and further contributes to healthcare disparities.36
Another unfavourable scenario for universal LS screening was 
to reduce the risk of CRC among relatives diagnosed with LS to 
25%, which increased the cost of the programme to CHF103 
385 per QALY above the cost- effectiveness threshold. Cumula-
tive risks of LS- associated cancers depend on sex and distribution 
of MMR gene pathogenic variants.2 MLH1 and MSH2 patho-
genic variants raise the lifetime risk of CRC to around 50%,37 
while PMS2 variants raise the lifetime risk of CRC up to 12% 
and 13% for endometrial cancer.2 32 Given that PMS2 patho-
genic variants are less frequent, we consider that a 40% CRC 
risk among relatives identified with LS through cascade testing is 
a realistic assumption, consistent with the German- based model 
(42% risk of CRC among LS cases by age 80 years) and with 
EGAAPP consensus.5 18 20
Finally, the cost of carrier testing for relatives and the cost 
of colonoscopy do not have substantial effects on ICER. Our 
model assumed 79% compliance with biannual colonoscopy.10 
Other studies reported colonoscopy compliance ranging from 
67% to 97%.20 38 39 Using one- way sensitivity analysis and prob-
abilistic sensitivity analysis, we varied compliance rates between 
58% and 100%. Decreasing colonoscopy compliance to 58% 
increased the cost- effectiveness ratio to almost CHF 81 000 
which is still below the cost- effectiveness threshold.
Our findings and parameters are compatible with cost- 
effectiveness analyses of LS screening conducted in the USA 
and in Australia. The US- based model demonstrated the cost- 
effectiveness of a strategy including IHC, BRAF and DNA 
sequencing with cascade testing of 12 relatives per LS case 
and ICER of $50 000 per life- year saved.10 Based on a second 
US- based model, using a predictive model to stratify individuals 
into different levels of cancer risk, followed by IHC and germ-
line DNA testing resulted in ICER of $35 143 per life- year saved 
with the age cut- off at 25–35 years.40 The Australian- based model 
showed a cost- effectiveness ratio of $61 235 per life- year saved 
with annual colonoscopy and with no age limit.19 Our findings 
are conflicting with a German- based model, reporting that the 
ICER of universal LS screening is €4 188 036, and it is not cost- 
effective compared with tumour- based screening.18 This substan-
tial difference in costs between the German and our model might 
be explained by several reasons. The German model assumed 
higher costs of DNA sequencing, lower number of tested rela-
tives per LS case, and lower proportion of cancer- free relatives 
participating in colonoscopy screening. In our model, one- way 
Figure 3 Tornado diagram. One- way sensitivity analysis for universal DNA sequencing (Strategy 2). The Y axis shows tested parameters and the X axis 
shows cost per QALY saved. The change in cost- effectiveness associated with 50% decrease in each parameter is depicted by the darker bars, which indicate 
higher cost per QALY saved (ie, less cost- effective), the change associated with 50% increase in each parameter is depicted by the lighter bars, which 
indicate lower cost per QALY saved (ie, more cost- effective). The solid vertical line represents the default cost- effectiveness ratio of CHF 65 058 per QALY 
saved. The dotted vertical lines indicate cost- effectiveness threshold of CHF 100 000 in Switzerland. CRC, colorectal cancer; LS, Lynch syndrome; QALY, 
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sensitivity analysis revealed that the number of tested relatives 
per LS case and the cost of germline DNA testing had the highest 
impact on overall cost- effectiveness ratio. In most studies, the 
number of tested relatives per LS case had the highest impact on 
results, despite substantial differences in input parameters.
The first limitation of our study is that we evaluated the cost- 
effectiveness of universal LS screening based solely on patients 
with CRC, while LS is also associated with other types of cancer, 
including endometrial cancer. We focused on CRC because it 
is commonly associated with the syndrome and affects both 
women and men. Including screening for endometrial cancer 
will probably increase the cost- effectiveness of universal LS 
screening, given strategies for early prevention and risk- reducing 
surgery.41 International groups further emphasise the impor-
tance of genetic testing of women with endometrial cancer for 
early identification of healthy LS cases.42 We also assumed that 
50% of relatives who refused cascade testing might undergo 
frequent colonoscopy screening. The exact proportion of rela-
tives undergoing frequent colonoscopies is unknown and our 
analyses may not be accurate regarding the potential benefits 
of universal LS screening. Our model did not account for the 
proportion of CRC cases identified with variants of unknown 
significance (VUS). VUS rate is reportedly 6% for MLH1/MSH2/
MSH6/EPCAM genes and 4% for PMS2,43 while Swiss lab experi-
ence indicates 10% frequency of VUS. Although these cases will 
not yield downstream cascade testing, they are managed with 
increased frequency of colonoscopy,44 which may yield changes 
in surveillance among relatives. Nevertheless, we acknowl-
edge that VUS cases will likely decrease the cost- effectiveness 
of universal genetic screening in real- world settings. Finally, in 
real- world settings, it is unlikely to obtain consent for germline 
genetic testing from 100% of CRC cases, which may have an 
effect on cost- effectiveness of universal LS screening. A Swiss- 
based single- centre study reported approximately 14% refusal 
rate of germline testing among patients with CRC.31 Our one- 
way sensitivity analyses showed that when only 50% of patients 
with new CRC accept germline testing, the overall cost of the 
alternative strategy increases to almost CHF78 000 per QALY 
saved, still below the cost- effectiveness threshold.
We demonstrate that universal LS screening with cascade 
testing of relatives results in substantial benefits for the Swiss 
healthcare system at a reasonable cost. Our findings provide 
evidence needed to inform policymakers, healthcare providers 
and insurance companies about the costs and health benefits 
associated with universal LS screening and cascade testing of 
relatives as a public health intervention, supporting NICE guide-
lines.45 The overall cost- effectiveness of this approach depends 
on the costs of DNA sequencing and the willingness of patients 
and relatives to be tested. The cost of DNA sequencing depends 
on how many genetic variations are analysed; during the past 
15 years, this cost has dramatically decreased, and it is foreseen 
that this trend will continue.46 Close coordination of different 
stakeholders, such as primary care providers, specialists, genetic 
clinicians and laboratories is crucial to encourage and educate 
the public about the importance of screening for LS. Further 
research needs to examine the cost- benefit ratio of universal LS 
screening, since individual preferences for genetic testing should 
be elicited and used in shared decision- making.47
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